A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician\'s choice of either Dacarbazine or Carboplatin and Paclitaxel
Epistemonikos ID: da01565c8a247bacaecfee8c39c841c8c843c5e3
First added on: Oct 21, 2017